Novel immunotherapeutic approaches to the treatment of urothelial carcinoma

Immunotherapy has long played a role in urothelial cancers with the use of bacille Calmette Guérin (BCG) being a mainstay in the treatment of nonmuscle invasive bladder cancer. Novel therapeutic approaches have not significantly impacted mortality in this population and so a renaissance in immunothe...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Urology 2016-06, Vol.8 (3), p.203-214
Main Authors: Muthigi, Akhil, George, Arvin K., Brancato, Sam J., Agarwal, Piyush K.
Format: Article
Language:English
Subjects:
Bladder cancer
Immunotherapy
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy has long played a role in urothelial cancers with the use of bacille Calmette Guérin (BCG) being a mainstay in the treatment of nonmuscle invasive bladder cancer. Novel therapeutic approaches have not significantly impacted mortality in this population and so a renaissance in immunotherapy has resulted. This includes recombinant BCG, oncolytic viruses, monoclonal antibodies, vaccines, and adoptive T-cell therapy. Herein, we provide a review of the current state of the art and future therapies regarding immunotherapeutic strategies for urothelial carcinoma.
ISSN:1756-2872
1756-2880
DOI:10.1177/1756287216628784